Fennec Pharmaceuticals Inc. Common Stock
Veridion Score
Composite trend over time
Why is FENC moving today?
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for FENC.
FENC insider activity
Fennec Pharmaceuticals Inc. Common Stock
5 insiders bought in the last 90 days
Net selling: -$2.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | 2026-06-10 | Cook Jodi A | Insider | buy | $8.70 | 20,000 | 160,000 | $174K | SEC Form 4 |
| 2026-06-10 | 2026-06-10 | Islam Khalid | Insider | buy | $8.70 | 25,000 | 250,000 | $218K | SEC Form 4 |
| 2026-06-10 | 2026-06-10 | Brughera Marco Maria | Insider | buy | $8.70 | 20,000 | 235,545 | $174K | SEC Form 4 |
| 2026-06-10 | 2026-06-10 | RALLIS CHRIS A | Insider | buy | $8.70 | 20,000 | 200,000 | $174K | SEC Form 4 |
| 2026-06-02 | 2026-06-01 | Raykov Rosty | Insider | buy | $2.45 | 15,597 | 1,556,195 | $38K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 43 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFENC contract awards, year to date.
Public federal awards linked to this ticker.
FENC lobbying filings, year to date.
Registered lobbying filings matched to Fennec Pharmaceuticals Inc. Common Stock.